IBSAL, CIC, IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain.
Transgenic Facility, Nucleus, University of Salamanca, Salamanca, Spain.
J Thromb Haemost. 2022 May;20(5):1248-1255. doi: 10.1111/jth.15672. Epub 2022 Feb 28.
Rare inherited thrombocytopenias are caused by alterations in genes involved in megakaryopoiesis, thrombopoiesis and/or platelet release. Diagnosis is challenging due to poor specificity of platelet laboratory assays, large numbers of culprit genes, and difficult assessment of the pathogenicity of novel variants.
To characterize the clinical and laboratory phenotype, and identifying the underlying molecular alteration, in a pedigree with thrombocytopenia of uncertain etiology.
PATIENTS/METHODS: Index case was enrolled in our Spanish multicentric project of inherited platelet disorders due to lifelong thrombocytopenia and bleeding. Bleeding score was recorded by ISTH-BAT. Laboratory phenotyping consisted of blood cells count, blood film, platelet aggregation and flow cytometric analysis. Genotyping was made by whole-exome sequencing (WES). Cytoskeleton proteins were analyzed in resting/spreading platelets by immunofluorescence and immunoblotting.
Five family members displayed lifelong mild thrombocytopenia with a high number of enlarged platelets in blood film, and mild bleeding tendency. Patient's platelets showed normal aggregation and granule secretion response to several agonists. WES revealed a novel nonsense variant (c.322C>T; p.Gln108*) in TPM4 (NM_003290.3), the gene encoding for tropomyosin-4 (TPM4). This variant led to impairment of platelet spreading capacity after stimulation with TRAP-6 and CRP, delocalization of TPM4 in activated platelets, and significantly reduced TPM4 levels in platelet lysates. Moreover, the index case displayed up-regulation of TPM2 and TPM3 mRNA levels.
This study identifies a novel TPM4 nonsense variant segregating with macrothrombocytopenia and impaired platelet cytoskeletal remodeling and spreading. These findings support the relevant role of TPM4 in thrombopoiesis and further expand our knowledge of TPM4-related thrombocytopenia.
罕见的遗传性血小板减少症是由巨核细胞生成、血小板生成和/或血小板释放相关基因改变引起的。由于血小板实验室检测的特异性差、致病基因数量多,以及新型变异致病性评估困难,导致诊断具有挑战性。
描述血小板减少症病因不明的家系的临床和实验室表型,并确定潜在的分子改变。
患者/方法:索引病例因终身血小板减少症和出血而被纳入我们的西班牙遗传性血小板疾病多中心项目。采用 ISTH-BAT 记录出血评分。实验室表型分析包括血细胞计数、血涂片、血小板聚集和流式细胞分析。采用全外显子组测序(WES)进行基因分型。通过免疫荧光和免疫印迹分析静止/扩展血小板中的细胞骨架蛋白。
5 名家族成员均表现为终身轻度血小板减少症,血涂片上可见大量大血小板,且有轻度出血倾向。患者的血小板对几种激动剂的聚集和颗粒分泌反应正常。WES 发现 TPM4(NM_003290.3)基因的一个新型无义变异(c.322C>T;p.Gln108*),该基因编码原肌球蛋白-4(TPM4)。该变异导致血小板在 TRAP-6 和 CRP 刺激后扩展能力受损、激活血小板中 TPM4 定位异常,以及血小板裂解物中 TPM4 水平显著降低。此外,该索引病例显示 TPM2 和 TPM3 mRNA 水平上调。
本研究鉴定了一种新型 TPM4 无义变异,与巨血小板减少症和血小板细胞骨架重塑及扩展受损相关。这些发现支持 TPM4 在巨核细胞生成中的重要作用,并进一步扩展了我们对 TPM4 相关血小板减少症的认识。